LONDON--(BUSINESS WIRE)--Ear infections have many risk factors, which include cold and flu season, injury to the ear, bacteria, and cigarette smoke. As there are several ways to contract an ear infection, there is a high demand for ear infection medicine and other treatments. Thus, the high-risk factors of ear infection will fuel the growth of the ear infection treatment market during the forecast period. Furthermore, this industry research report also presents a competitive analysis of the market by geography (North America, Europe, Asia, and ROW) and by infection type (middle ear, outer ear, and inner ear).
Competitive vendor landscape
The global ear infection treatment market is highly competitive with major vendors such as GlaxoSmithKline, Johnson & Johnson, Novartis, Otonomy, and Pfizer, competing on the basis of price, quality, and market presence.
“Surgery is often the best treatment for patients with chronic ear infections. Thus, companies in the market have been engaging in continuous R&D to develop diagnostic devices and surgical procedures. The development in these areas will make surgical procedures safer and more comfortable, thereby, driving the growth of the ear infection treatment market,” says a senior analyst at Technavio.
Top five ear infection treatment market vendors
GlaxoSmithKline
GlaxoSmithKline is one of the most established companies in the global healthcare that operates under various segments including pharmaceuticals, vaccines, and consumer healthcare. Under its ear infection treatment category, the company offers AMOXIL, and NEOSPORIN H ear drops.
Johnson & Johnson
Johnson & Johnson is a household name across several countries. The company owns and operates businesses under three segments namely consumer, pharmaceutical, and medical devices. The company offers POLYSPORIN + Pain Relief Ear Drops, which contains 10,000 units polymyxin B (as sulfate) and 50 mg lidocaine hydrochloride.
Novartis
Novartis has business operations under three segments, namely innovative medicines, Sandoz, and Alcon. The company offers CIPRODEX ear drops that contain ciprofloxacin and dexamethasone. Ciprofloxacin is an antibiotic that treats certain types of bacteria. Dexamethasone is a steroid drug that reduces inflammation.
Otonomy
Otonomy is engaged in the development of innovative therapeutics for otology. The company’s key offering in the market includes OTIPRIO, which is a sterile, preservative-free, otic suspension of 6% ciprofloxacin administered as a single-dose.
Pfizer
Pfizer owns and operates under two business segments: innovative health and essential health. The company offers ZITHROMAX for the treatment of ear infection, which contains the active ingredient azithromycin, a subclass of macrolide antibiotics, for oral administration. ZITHROMAX tablets contain azithromycin dihydrate equivalent to 600 mg azithromycin.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.
Browse Related Reports:
- Global Middle Ear Implants Market 2019-2023 - The market research study identifies Cochlear Ltd., Envoy Medical Corporation, MED-EL Medical Electronics, Medtronic, Olympus Corporation, and Ototronix, as the leading players in the global middle ear implants market.
- Global Hearing Aid 3D Printing Devices Market 2019-2023 - The market research study identifies 3D Systems Inc., 3Shape AS, EnvisionTEC, Materialise, and Rapid Shape GmbH, as the leading players in the global hearing aid 3D printing devices market.
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
